CTOs on the Move

Eloxx Pharmaceuticals

www.eloxxpharma.com

 
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Eloxx Pharmaceuticals raised $30M on 06/09/2017

Similar Companies

Alfa Aesar

Alfa Aesar, a Johnson Matthey Company, is a leading international manufacturer and supplier of research chemicals, metals and materials. With 30,000 products listed in the catalogue, Alfa Aesar is the single source for customers' chemical and material

F-star Biotechnology

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients.

Crucell Biologics

Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of

PRA International

PRA International is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allegro Ophthalmics

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.